Arrivent Biopharma Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Arrivent Biopharma Inc's ROI in the second quarter of 2026?
Arrivent Biopharma Inc recorded a cumulative net loss of $-164 million during 12 months ending in the second quarter of 2026, resulting in a negative return on investment (ROI) of -50.25%.

Within the Healthcare sector 409 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2026 from 3563 to 3707.

Definition and Formula of Return on Investment

Select the Comparisons :

None ▼

Select the Ratio:

Return on Investment ROI▼

None ▼

Return on Investment ROI▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Investment	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Investment Change TTM	31.97 %	14.68 %	-7.41 %	37.35 %	114.01 %
Y / Y Net Income Change TTM	-	-	-	-	-
Investment (TTM) in Millions	367	324	307	305	250
Return On Investment (TTM)	-50.25 %	-48.97 %	-62.48 %	-59.66 %	-55.48 %
AVBP's Overall Ranking	# 3707	# 3563	# 2498	# 2798	# 3091
Seq. Investment Change TTM	9.86 %	11.44 %	4.88 %	2.78 %	-4.53 %
Seq. Net Income Change TTM	-	-	-	-	-
Net Income (TTM) in Millions	-164	-145	-166	-151	-137

AVBP Company Profile >> Back to AVBP Roi Comparisons >> See Annual AVBP Return On Investment

Return On Investment AVBP's Ranking
Within:	No.
Industry	# 169
Sector	# 410
Overall	# 3707

Return On Investment Statistics
High	Average	Low
-21.92 %	-47.01 %	-62.48 %
(Mar 31 2024)		(Dec 31 2025)

Financial Statements
Arrivent Biopharma Inc's II. Quarter Investments	$ 367 Millions	AVBP's Balance sheet
Arrivent Biopharma Inc's II. Quarter Income	$ -50 Millions	Quarterly AVBP's Income Statement
AVBP's Income by Division		See AVBP's Income by Division

AVBP Annual Return On Investment	(Dec 31 2025) 2025	(Dec 31 2024) 2024
Total Investments in Millions	307	258	0	0	0
Y / Y Investment Growth	19.23 %	-	-	-	-
Net Income in Millions	-166	-80	0	0	0
Y / Y Net Income Growth	-	-	-	-	-
Annual Return On Investment	-54.13 %	-31.24 %	-	-	-

Annual Roi Comment

Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
AVBP's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for AVBP's Competitors
Subscribers only: Roi for Arrivent Biopharma Inc's Suppliers
Subscribers only: Return On Investment for AVBP's Customers

Other Ratios
AVBP's Roa	AVBP's Inventory Turnover Ratio	AVBP's Growth Rates	AVBP's Dividend Statistics
	AVBP's Profitability Ratios	AVBP's Asset Turnover Ratio	AVBP's Dividend Growth
AVBP's Roe	AVBP's Valuation Ratios	AVBP's Financial Strength Ratios	AVBP's Dividend Payout Ratio

Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector

ROI

Date modified: 2026-09-04T10:02:21+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.